SCHEMBL16509013

SCHEMBL16509013

CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)NC)[C@@H](C)O

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 7/20 0.49
▸ NPY5R Q15761 6/20 0.49
▸ NPY1R P25929 5/20 0.49
▸ NPY2R P49146 3/20 0.49
▸ GLP1R P43220 2/20 0.46
▸ GCGR P47871 1/20 0.46
▸ GIPR P48546 1/20 0.46
▸ TLR2 O60603 1/20 0.44
▸ NMT2 O60551 1/20 0.43
▸ NMT1 P30419 1/20 0.43
▸ ECE1 P42892 1/20 0.43
▸ MUS81 Q96NY9 1/20 0.43
▸ RAMP3 O60896 4/20 0.42
▸ CALCR P30988 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16509016 0.96 NPY4R (0.45) NPY4RNPY5RNPY1RNPY2RGLP1R
SCHEMBL16508981 0.96 NPY4R (0.45) NPY4RNPY5RNPY1RNPY2RGLP1R
SCHEMBL16509029 0.94 NPY4R (0.51) NPY4RNPY5RNPY1RNPY2RGLP1R
SCHEMBL16509119 0.94 NPY4R (0.51) NPY4RNPY5RNPY1RNPY2RGLP1R
SCHEMBL16507940 0.93 GLP1R (0.46) NPY4RNPY5RNPY1RNPY2RGLP1R
SCHEMBL16509114 0.92 GLP1R (0.48) GLP1RGCGRGIPRTLR2NMT2
SCHEMBL16509065 0.91 NPY4R (0.57) NPY4RNPY5RNPY1RNPY2R
SCHEMBL16507975 0.90 NPY4R (0.43) NPY4RNPY5RNPY1RNPY2RGLP1R
SCHEMBL16508995 0.89 NPY4R (0.59) NPY4RNPY5RNPY1RNPY2RTLR2
SCHEMBL16508084 0.89 GLP1R (0.46) NPY4RNPY5RNPY1RGLP1RGCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301087-A1 CRF1 RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. 2011-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301087-A1 CRF1 RECEPTOR COMPOUNDS CRHR1, CRH, CRHR2 NPY4R 109/4885NPY5R 149/4885NPY1R 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback